DNLI Research and Charts

DNLI - Denali Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2026-05-28 (Delayed quote data 2026-03-24)

Last 20.97	Change ⇓ -0.12 (-0.57%)	Volume 1,627,456
	Open 20.73	High 21.21	Low 20.54

8EMA (Daily) 20.62	40EMA (Daily) 20.24	50EMA (Daily) 20.02	STO (Daily) 50.359	MACD Hist (Daily) 0.015
8EMA (Weekly) 20.219	40EMA (Weekly) 18.19	50EMA (Weekly) 18.14	STO (Weekly) 61.400	MACD Hist (Weekly) -0.034


Company Profile
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.